Forest Says Namenda Buyers Can't Use Its Own Consultant

Law360, New York (June 16, 2017, 4:55 PM EDT) -- Forest Laboratories LLC on Thursday asked a New York federal court to disqualify Namenda buyers’ expert witness, as he consulted with the drug company for nearly 15 years, including on the patent litigation at the heart of this pay-for-delay proposed class action.

Dr. Lon Schneider consulted with Forest starting in at least 2003, during the process to get the Alzheimer’s medication approved, and then during subsequent patent and antitrust litigation, Forest said, adding that he remains on the Namenda advisory board. There is no way he...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.